SB 180-FN (2024): relative to product labeling and information guide requirements for cannabis products and the prohibition of the sale of hemp products containing certain levels of THC.

SB 180-FN (2024)

relative to product labeling and information guide requirements for cannabis products and the prohibition of the sale of hemp products containing certain levels of THC.

• Status: Referred for interim study
• Term: 2023-2024
• House committee: Commerce and Consumer Affairs
• Senate committee: Judiciary
• Subject: Public and Mental Health

The Story

It was introduced on January 19, 2023 and referred to the Senate Judiciary committee. The committee held a public hearing on January 31, 2023. The committee voted unanimously, 5–0, to recommend that the Senate pass it with changes (amendment 2023-0589s), and the report was placed on the consent calendar. The committee's amendment (2023-0589s) was adopted on a voice vote on February 22, 2023, changing the text of the bill. On February 22, 2023 the Senate voted to pass it with changes on a voice vote and ordered it to a third reading. It crossed to the House on March 16, 2023 and was referred to the House Commerce and Consumer Affairs committee. The committee held a public hearing on April 26, 2023. The committee held a work session on April 26, 2023. The committee met in executive session on May 10, 2023 to vote on its recommendation. The committee retained the bill, holding it for further work rather than reporting it out this year. The committee held a work session on September 20, 2023. The committee met in executive session on November 8, 2023 to vote on its recommendation. The committee voted unanimously, 19–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On January 3, 2024 the House voted to study it after the session ends on a voice vote. The committee held a work session on September 12, 2024. The committee met in executive session on October 17, 2024 to vote on its recommendation. The committee reported back on its interim study of the bill: “Not Recommended for Future Legislation”, by a vote of 16 to 0.

Sponsors

• Sen. Kevin Avard (R - SD12) (prime sponsor)
• Sen. Sharon Carson (R - SD14)
• Sen. Bill Gannon (R - SD23)

Hearings and Sessions

• January 31, 2023, 1:30 PM: hearing, Senate Judiciary, SH 100
• April 26, 2023, 10:00 AM: public hearing, House Commerce and Consumer Affairs, LOB 302-304
• April 26, 2023, 1:15 PM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
• May 10, 2023, 2:00 PM: executive session, House Commerce and Consumer Affairs, LOB 302-304
• September 20, 2023, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
• November 8, 2023, 1:30 PM: executive session, House Commerce and Consumer Affairs, LOB 302-304
• September 12, 2024, 10:00 AM: full committee work session, House Commerce and Consumer Affairs, LOB 302-304
• October 17, 2024, 10:00 AM: executive session, House Commerce and Consumer Affairs, LOB 302-304

Votes

• February 22, 2023, Senate: Ought to Pass with Amendment 2023-0589s — voice vote, passed
• January 3, 2024, House: Refer for Interim Study — voice vote, passed

The Docket

Laws It Would Change

• RSA 126-X:12
• RSA 439-A

Related Bills

• HB 611-FN (2023): relative to eligibility criteria for the therapeutic cannabis program and establishing a commission to study state-controlled sales of cannabis and relative to the prohibition on the sale of hemp products containing certain levels of THC.

From the General Court

• Bill text
• Bill status page
• Docket
• SC 8
• SC 11
• HC 36
• HC 42
• HC 49, page 6